Abstract | Clinical oncology is being revolutionized by the increasing use of molecularly targeted therapies. This paradigm holds great promise for improving cancer treatment; however, allocating specific therapies to the patients who are most likely to derive a durable benefit continues to represent a considerable challenge. Evidence continues to emerge that cancers are characterized by extensive intratumour genetic heterogeneity, and that patients being considered for treatment with a targeted agent might, therefore, already possess resistance to the drug in a minority of cells. Indeed, multiple examples of pre-existing subclonal resistance mutations to various molecularly targeted agents have been described, which we review herein. Early detection of pre-existing or emerging drug resistance could enable more personalized use of targeted cancer therapy, as patients could be stratified to receive the therapies that are most likely to be effective. We consider how monitoring of drug resistance could be incorporated into clinical practice to optimize the use of targeted therapies in individual patients. REVIEWS NATURE REVIEWS | CLINICAL ONCOLOGY VOLUME 13 | JUNE 2016 | 335 © 2 0 1 6 M a c m i l l a n P u b l i s h e r s L i m i t e d . A l l r i g h t s r e s e r v e d .
For the past seven decades, cancer therapy has been defined by use of nonselective cytotoxic agents. Historically, the choice of treatment was determined by the histological features of the tumour and the clinical characteristics of the patient, with limited or no focus on targeting the specific molecular aberrations that bestow tumour cells with the ability to proliferate abnormally and uncontrollably. Unsurprisingly, this untargeted cyto toxic approach all too frequently results in substantial toxicity with only marginal clinical benefit.
In the past decade, however, a dramatic change in emphasis has permeated medical oncology, driven by the availability of a rapidly growing number of rationally designed therapies that target specific molecular alter ations in the tumour. Only a modest number of such drugs are currently available for use in routine clini cal practice (TABLE 1) , although many more are being evaluated in clini cal trials. These targeted therapies are often paired with an associated diagnostic assay, which is used to test for the presence of a molecular alteration that indicates whether the patient is likely to respond to the specific drug.
This approach is conceptually appealing, but response rates to targeted agents can be low, cures are infrequent, and drug resistance often develops rapidly. A targeted therapy will result in significant clinical improvement only if the target is both ratelimiting in terms of effects on tumour growth and present in most or all of the tumour cells. Within any given patient, however, cancer can be extremely heterogeneous in nature, reflecting a continuously evolving population of tumour cells 1 . Largescale tumour sequencing efforts have revealed that most human cancers have a substantial burden of clonal mutations, defined for the purposes of this manuscript as mutations that are shared by most or all of the malignant cells in the sequenced tumour sample -and thus arose in the founding clone 2, 3 . Growing evidence indicates that cancers also contain many subclonal mutations, defined as mutations that are present in a few cells, or perhaps a substantial minority of the tumourcell population. These subclones are derived from the founding clone, and are defined by the additional mutations they carry, which are not present in the bulk population. Of note, many subclonal mutations are not detected using routine clinical assays because their abundance often falls below the lower limit of sensitivity; tumour sampling issues can also lead to subclonal m utations being missed.
To be effective, targeted therapies need to be directed at the founding clonal mutations shared by all of the billions of cells in the cancer. For a few cancers that are heavily dependent on a single driver mutation, treat ment that targets this mutation is potentially curative. For example, acute promyelocytic leukaemia is driven by the promyelocytic leukaemia protein (PML)-retinoic acid receptor α (RARA) fusion protein, which can be effectively targeted via treatment with alltrans retinoic acid (ATRA) and arsenic 4 . Subclonal mutations are fre quently present in a variable proportion of the cancer cells in this disease 5 , but these subclones remain sus ceptible to ATRA and arsenic because they are derived from the founding clone harbour ing the treatment sensitizing PML-RARA fusion protein; thus, the dis ease remains curable. Occasionally, point mutations in the PML and RARA genes can drive resistance to this standard treatment, and the presence of these genetic alterations in even a small fraction of the cancer cells precludes cure with ATRA-arsenic therapy alone 6 . For most cancer types, therapies directed against a single molecular target are not durably curative owing to abundant similar forms of resistance; if subclones are present that bear mutations conferring resistance to therapy, these cells will rapidly expand and repopu late the tumour during treatment (FIG. 1) . Hence, if this preexisting drug resistance could be identified, patients could avoid the toxicity of drugs that are ultimately des tined to fail, and instead pursue alternative treatments with a higher probability of success.
Herein, we first review the evidence for extensive genetic heterogeneity within human cancers, which represents a preexisting repository of drugresistant subclones. We next consider the major molecularly tar geted therapies in current use, and associated resistance mechanisms that arise from selection and expansion of preexisting drugresistant cells. Finally, we discuss the clinical potential for early detection of drug resistance, as well as important limitations, and describe ways in which to incorporate highsensitivity detection of preexisting drug resistance into the next generation of cancer therapies.
Tumour heterogeneity
At a fundamental level, cancer is a disease of somaticcell evolution that is driven by successive waves of natural selection 7 . Genetic and epigenetic heterogeneity within a tumourcell population serves as the repository of selectable variation that fuels both disease progression and acquisition of resistance to therapy. The conceptual parallel between neoplastic evolution at a cellular level and Darwinian evolutionary processes among organisms was recognized more than 40 years ago 8, 9 , but until the past decade, remained largely a conceptual abstraction. Following the publication of the first tumour genome sequencing reports, mutational heterogeneity has come to the forefront as a recognized hallmark of cancer 10 , and has garnered more widespread attention.
The extraordinary variety of mechanisms by which different tumours, even within a given cancer type, acquire their neoplastic growth properties was one of the earliest and moststriking findings of cancer genome sequencing efforts. The mutations identified using these s quencing approaches are predominantly clonal in origin -that is, they are shared by most of the malignant cells within an individual cancer. Heterogeneity in the overall burden of clonal mutations among different tumours highlights the role of stochastic mutational events early in tumour development before clonal outgrowth. A particularly large burden of clonal mutations has been noted in some tumour types, such as melanoma, which have historically been associated with rapid development of drug resistance 11 . Whether this relationship reflects a relatively greater number of subclonal mutations -that, is mutations present in only a minority of cells -remains to be s ystematically examined for most cancers.
Using highthroughput DNAsequencing methodol ogies, studies have begun to examine both intermixed and spatially distinct tumourcell subclones within a variety of tumour types [12] [13] [14] . These subclones carry distinct sets of oncogenic driver mutations and other phylogenetic signatures of their unique, and ongoing, evolutionary history 15, 16 . Subclonal mutations arise initi ally in a single cell; this cell can then expand to become a detectable minority population within the tumour. The mutations that confer a growth advantage -frequently referred to as 'driver mutations' -can occur in concert with additional unselected mutations. Subclonal driver mutations can be clinically significant; for example, in patients with chronic lymphocytic leukaemia (CLL), the presence of subclonal driver mutations predicts morerapid disease progression 17 , and mutations in TP53, which when clonal are predictive of survival, are equally predictive if present in a minority subclone 18 . The unselected 'passenger mutations' are also relevant, as these mutations -as well others that arise continu ally in single cells as the consequence of inevitable errors that occur during DNA replication -can function as a reservoir of genetic diversity from which resistance to subsequent therapies can emerge. Indeed, prevalent genetic changes identified in relapsed tumours following initial therapy have been found to be present at a much lower frequency before treatment (that is, in minor ity tumour subclones), implying that d rugresistanc e was preexisting 16, 19, 20 . Intuitively, a greater burden of subclonal mutations might be predicted to confer increased potential for rapid tumour evolution. Indeed, greater intratumour genetic heterogeneity, as assessed by a variety of met rics, seems to portend worse outcomes for patients with several cancer types, including head and neck 21, 22 , cer vical 23 , and breast cancers 24 , among others 25 . Moreover, in patients with the premalignant condition Barrett oesophagus, clonal diversity has been demonstrated to be proportional to the risk of progression to oesopha geal adenocarcinoma 26 . The total mutation burden in a tumour is proportional to both the number of tumour cells and the frequency of mutations per cell genome. In
Key points
• All cancers probably contain an enormous number of coexisting subclonal mutations; in some cases, every possible mutation could exist in at least one cell in the tumour • Resistance to molecularly targeted therapies can arise from selective growth of pre-existing subclones within the bulk of the tumour that carry drug-resistance mutations and thus have a survival advantage • Drug-resistance mutations can be found in variable proportions of tumour cells before therapy; their early detection enables stratification of patients to more-effective treatments and avoidance of treatments that are destined to fail • Accurate identification of resistance mutations requires highly sensitive detection techniques and representative tumour sampling • Routine interrogation of the subclonal genetic structure of tumours will be critical to the success of personalized cancer medicine aggressive triplenegative breast cancer (TNBC), the rate of mutation accumulation is more than an order of mag nitude greater than that of the more indolent oestro gen receptor (ER)positive disease subtypes 27 . The high mutation rate could conceivably contribute to the worse outcomes of patients with TNBC, and the tendency of TNBCs to acquire the ability to m etastasize at a smaller primarytumour size 28 . Interestingly, a higher overall mutational burden does not invariably indicate a worse prognosis for patients. For example, in colorectal cancer (CRC), mismatch repair (MMR) deficiency results in a 'hypermutator' phenotype, and can be associated with the presence of greater than 100fold more somatic variants than are detected in their MMRintact disease counterparts. Despite this increased mutational load, patients with MMRdeficient CRCs have a morefavourable prognosis than those with MMRintact disease for reasons that are incompletely understood 29 . One hypothesis is that the markedly elevated mutation frequency in the former might exceed some ceiling of somatic evolutionary bene fit, which then leads to 'error catastrophe' that hinders growth of the tumour 30 . Alternatively, the high mutation rate might result in the generation of a larger number of immunogenic neoantigens, leading to moreeffective immune control of MMRdeficient tumours. This latter concept has been supported by the observation that melan omas with the largest burden of clonal mutations are the mostlikely to respond to immunotherapies 31 , and more recently, that MMRdeficient colon cancers are uniquely responsive to immunecheckpoint blockade, compared with MMRintact tumours 32 . Genetic heterogeneity is an intrinsic feature of cancer 1, 10 ; a higher level of genetic heterogeneity is associ ated with a moreaggressive disease course, at least in several cancer types [21] [22] [23] [24] [25] [26] , suggesting that this pheno type contributes to development of therapy resistance and disease progression. In the era of highly targeted antineoplastic agents, the presence of preexisting vari ants that impart therapy resistance within these hetero geneous populations is of increased relevance and is now, arguably, the most substantial barrier to achieving durable cures.
Targeted agents and drug resistance
In the following sections we review selected targeted thera pies that are associated with a specific, testable molecular alteration. This selection is not all encompassing, and the list of such agents is certain to expand in the near future; our intent is to provide a conceptual overview based on the current clinical landscape.
Tyrosine kinase inhibitors targeting ABL1
Nearly all patients with chronic myeloid leukaemia (CML) have disease that is driven by the BCR-ABL1 gene fusion 33 . ABL1 is a nonreceptor tyrosine kinase that is involved in regulation of multiple cellular pro cesses, including cell division 34 . ABL1 normally shuttles between the cytoplasm and nucleus; however, when fused with BCR (breakpoint cluster region protein), the ABL1 kinase is constitutively activated and becomes retained in the cytoplasm. Activated ABL1 then results in aberrant signalling and promotes uncontrolled cell proliferation through several routes, including the MAPK, JAK-STAT, and PI3K pathways 34 . Inhibition of the ABL1 kinase with imatinib is the prototypical, and arguably most successful, example of targeted cancer therapy: 98% of patients with CML responded to imatinib in initial trials of this agent, and 5year survival rates for patients with this disease improved from 30% among patients treated with inter feronα plus cytarabine to 89% in those treated with imatinib 35 . In addition, approximately 20% of patients with primary acute lymphoblastic leukaemia (ALL) har bour the BCR-ABL1 fusion 36 , and these patients can also benefit from treatment with imatinib 37 . Despite the remarkable effectiveness of imatinib, patients commonly develop resistance to therapy. Imatinib resistance is predominantly driven by point mutations in the ABL1 kinase that interfere with drug binding to the protein; more than 100 different mutations have been reported 38 . Resistance mutations identified at the time of clinically observed treatment failure have often been detected to be present at a low frequency at the time of diagnosis -before the initiation of therapy [39] [40] [41] . Resistance can thus arise via selective growth of cells with a single ABL1 mutation (monoclonal resistance), although simul taneous outgrowth of multiple drugresistant subclones (polyclonal resistance) has also been reported 42 . Additional ABL1 tyrosinekinase inhibitors (TKIs) have now been approved by the FDA for the treatment of leukaemias harbouring the BCR-ABL1 fusion. Second generation TKIs, including bosutinib, dasatinib and nilo tinib, overcome many imatinibresistance mutations in BCR-ABL1, and such agents can be used either as initial therapy or following development of resistance to this agent 38 . Importantly, specific mutations in BCR-ABL1 confer resistance to specific inhibitors. For example, the Y253H mutation results in resistance to imatinib and nilotinib, but BCR-ABL1 kinases with this alteration remain sensitive to dasatinib 38 . Of note, the BCR-ABL1 T315I 'gatekeeper' mutation confers resistance to all currently approved ABL1 TKIs other than the newest of these agents, ponatinib 38 . Sequencing of the ABL1 gene is typically carried out after failure of initial TKI therapy to help select an alternative noncrossresistant TKI, based on the resistance mutation found 43 . Genotyping of ABL1 is most commonly performed using conventional Sanger DNAsequencing methods, which can only detect mutations present in >10% of cells in the sam pled popu lation 44 ; mutations conferring TKIresistance with an incidence below this limit will, therefore, go undetected. Mass spectrometry, which enables sensi tivities of mutation detection of 0.05-0.5%, has been used to investigate subclonal TKIresistance mutations at the time of relapse 45 . Among 220 patients with CML studied after development of resistance to imatinib treatment in a retro spective analysis 45 , 55 mutations associ ated with resistance to secondline therapies (dasatinib and nilotinib) were identified in 50 patients DNA-replication errors can introduce increasing genetic diversity at every cell division after the clonal founding of a tumour; thus, considerable genetic heterogeneity exists in the tumour at the time of diagnosis. As a consequence, a small subset of tumour cells with mutations that confer resistance to particular therapies will often be present (represented by purple shading). Initially, this population of drug-resistant cells have no specific growth advantage and expand at the same overall rate as the entire tumour; however, with introduction of a therapeutic pressure that hinders the growth of all but the resistant cells, the latter will rapidly take over the tumour, becoming the predominant clone, until another non-cross-resistant treatment is applied. Previously, a lack of sufficiently sensitive tools to detect these rare subclones meant that resistance could only be identified using clinical criteria, such as radiographic imaging, at a relatively late stage of disease. Now, novel molecular means for identifying resistance mutations (see 'Detecting pre-existing drug resistance' section) are enabling iteratively earlier detection of drug resistance as technical sensitivity improves, and are thus increasing the opportunity to better customize therapy.
using conventional Sanger sequencing. By contrast, mass spectrometry enabled 105 such resistance muta tions to be identified in 71 patients. The majority (84%) of mutations detected in this retrospective analysis were found to rapidly become the dominant clones in patients who were treated with the drug to which the mutation conferred resistance. Among 100 patients with chronic phase CML, those found to have subclonal resistance mutations had a much worse outcome, with 0% failurefree survival after secondline therapy ver sus approximately 50% failurefree survival in patients who lacked subclonal resistance mutations 45 ; some of the unexplained treatment failures in this latter group could conceivably have resulted from mutations present below the detection limits of mass spectrometry.
Interestingly, the presence of lowfrequency muta tions following imatinib failure is associated with worse clinical outcomes in patients treated with second generation TKIs, even if the mutations were not pre dicted to confer resistance to the inhibitor used 46 . Thus, subclonal diversity itself might be a marker of the poten tial to evolve drug resistance, and therefore could be an important prognostic indicator.
Tyrosine kinase inhibitors targeting KIT
KIT is a receptor tyrosine kinase -also targeted by imati nib (TABLE 1) , that is overexpressed in >90% of gastro intestinal stromal tumours (GISTs) 47 . KIT is typically activated only when bound by KIT ligand (also known as stem cell factor or mast cell growth factor), which leads to activation of several cell growth pathways, including the MAPK and PI3K pathways 48 . KIT overexpression can lead to unregulated cell growth, as can constitutively activating point mutations affecting this protein, which are found in approximately 80% of GISTs 47 . KIT muta tions predominantly confer sensitivity -rather than resistance -to imatinib 47 . Patients who lack KIT muta tions frequently harbour mutations in the related receptor tyrosine kinase plateletderived growth factor receptor α (PDGFRA), which can also confer sensitivity to imati nib 49 . Historically, patients with GIST had a low response rate to chemotherapy, but treatment with imatinib induces marked clinical responses and has improved the median survival of patients with advancedstage GIST from 18 months to 57 months 50 . Unfortunately, most patients develop imatinib resistance within 2 years of starting therapy, predominately as a result of secondary mutations in the kinase domain of KIT or PDGFRA 51 . Alternate TKIs can be used in the setting of imati nib resistance, and differential sensitivity to second line TKIs depends on the specific imatinibresistance mutation involved 52 . Mutational profiling of KIT at the time of diagnosis can have prognostic and predictive value. For example, patients with exon 11 mutations generally have good responses to imatinib and improved survival; patients with exon 9 mutations, by contrast, are relatively resistant to imatinib, although resistance can be overcome to some extent by treatment with an elevated dose of imatinib 53 . Interestingly, the KIT protein has equivalent sensitivity to imatinib in vitro regardless of whether the activating mutation is located in exon 9 or exon 11 54 . The differential imatinib sensitivity of tumour cells harbouring these mutations in vivo has been hypothesized to reflect altered apoptotic thresholds that arise as a consequence of d ownstream signalling from the various mutant proteins 54 .
Results from mathematical modelling investigations suggest that imatinibresistant subclones probably pre exist in many GISTs before the initiation of therapy 55 . As in patients with CML, if these resistant subclones could be detected early in the disease course, use of a higher dose of imatinib or of an alternative TKI could be considered in the firstline setting. Moreover, signal ling downstream of KIT and PDGFRA is largely through the PI3K-mammalian target of rapamycin (mTOR) and MAPK pathways, and therapeutic targeting of these c ascades in GIST is currently an area of active investigation 56 .
MAPK pathway inhibitors
The MAPK pathway is a key cellular signalling circuit that is involved in sensing and responding to extra cellular stimuli, such as growth factors or inflammatory mediators (FIG. 2) . The stimulus (ligand) binds to and promotes dimerization of a receptor tyrosine kinase, such as KIT, PDGFRA, or EGFR, resulting in activation of the intra cellular kinase domain of the receptor. The kinase domain mediates phosphorylation of a RAS pro tein (HRAS, KRAS, or NRAS), which then phos phory lates RAF kinases (ARAF, BRAF, or CRAF), causing their dimerization and activation. Dimeric RAF then phosphory lates MEK, which in turn phosphorylates ERK, which can subsequently enter the cell nucleus and regulate the activity of a variety of transcription factors to modu late gene expression. In this manner, the MAPK pathway drives cell growth, and thus constitutive activation of any of its components can contribute to cancer. Multiple FDAapproved targeted drugs are specifically directed at proteins in this pathway (TABLE 1) , with many more in development. To date, the RAS family, despite being the mostmutated class of oncogenes in human cancers, has proved to be extremely d ifficult to selectively target 57 .
Targeting EGFR. Activating mutations in EGFR are found in approximately 15% of patients with nonsmall cell lung cancer (NSCLC) in the USA, and are particu larly common in some Asian populations, in which they can be found in up to 62% of patients 58 . Patients har bouring these mutations can be treated with TKIs that target this receptor (TABLE 1) , such as erlotinib 59 , afati nib 60 , or gefitinib 61 , which have been shown to greatly improve outcomes. For example, in the OPTIMAL trial 59 , progressionfree survival with erlotinib mono therapy in Chinese patients with advancedstage NSCLC and activating mutations in EGFR was 13.1 months, rela tive to 4.6 months in patients treated with gemcitabine plus carboplatin.
Erlotinib is also approved for the treatment of patients with pancreatic cancer, although in this setting, use of this agent is not contingent on the presence of an activating mutation in EGFR. In a phase III study of erlotinib plus gemcitabine versus gemcitabine alone, the addition of erlotinib to therapy resulted in a small, but statistically significant, median overall survival benefit of approximately 2 weeks (HR 0.82; P = 0.038) 62 . A more recent randomized trial conducted in Taiwan reported a median overall survival of 7.2 months in patients treated with erlotinib plus gemcitabine versus 4.4 months among those treated with gemcitabine alone 63 .
In patients with NSCLC, detection of activating muta tions in EGFR has generally been performed using the relatively lowsensitivity Sanger sequencing method. In a study in which EGFR mutations were evaluated using the moresensitive approach of nextgeneration sequen cing (NGS), investigators found that 22 of 87 patients with NSCLC who were considered to have wildtype EGFR based on the results of Sanger sequencing, in fact, harboured an EGFR mutation 64 . In another study, the investi gators used a mutationspecific PCRbased assay and demonstrated that patients carrying EGFRactivating mutations below the level of detection achievable with traditional methods of genotyping also derived benefit from the use of EGFRtargeted TKIs; the proportion of cells that were mutated was correlated with response rates and survival following EGFR blockade 65 . Results of a metaanalysis have confirmed the improved ability to stratify patients who are likely to benefit from EGFRTKI treatment with the use of highersensitivity genotyping assays 66 . These empirical observations are biologically plausible: NSCLC is characterized by a high level of intra tumour heterogeneity and thus key driver genes can be present in only a subset of tumour cells 67, 68 . As with other targeted therapies, acquired resistance to EGFR inhibitors is common. In a cohort of patients with NSCLC who became resistant to erlotinib, resist ance was caused by a second activesite mutation in EGFR, the T790M 'gatekeeper' mutation, in approxi mately 50% of patients 69 . Mutations or overexpression of downstream components of the MAPK pathway, such as KRAS, NRAS, BRAF, and MET, can also drive resistance to EGFR inhibitors, via constitutive pathway activation without dependence on EGFR 70 . In cellline models, subclonal populations harbour ing the EGFR T790M mutation have been found to pre exist before treatment with erlotinib, and clonally expand upon drug exposure 20 . This pattern also seems to hold true in vivo; in one study in which investigators compared the sensitivity of Sanger sequencing to that of mass spectrom etry for analysis of DNA mutations in tumour tissue sam ples, the fraction of patients with a detectable preexisting EGFR T790M mutation increased from 2.8% to 25.2% with the use of the latter technique 71 . In an independent massspectrometrybased study, investigators also found a 25% incidence of preexisting EGFR drug resistance mutations in tumour samples from patients with NSCLC, and furthermore, investigators reported that the relative abundance of the mutation was proportional to the extent of both progressionfree and overall survival 72 . EGFR is also the target of therapeutic antibodies used in patients with CRC (panitumuab or cetuximab), and head and neck cancer (cetuximab). In these patients, the presence of an activating EGFR mutation is not a requirement for use of antiEGFR antibody therapy, and resistance is not typically mediated by mutations in EGFR itself. However, preexisting activating mutations in the KRAS gene, which encodes a small GTPase that mediates signalling downstream of the EGFR (FIG. 2) , are common in patients with CRC and functionally bypass EGFR blockade 73 . For this reason, the antiEGFR anti bodies panitumumab and cetuximab are approved by the FDA for the treatment of CRC only in patients who lack mutations in KRAS 74 . The presence of KRAS mutations is also associated with a poor response to EGFR inhib ition in patients with NSCLC, although tumour samples are not routinely tested for such mutations in this set ting 75 . As with testing for EGFR mutations in patients with NSCLC, the clinical benefit of KRASmutation detection is heavily dependent on assay sensitivity. In patients with CRC who are deemed KRAS wild type at the time of diagnosis, treatment with antiEGFR antibody therapy frequently results in emergence of KRAS mutations 76 . These KRAS mutations might have been present at the time of diagnosis, below the detection limit of conventional DNAsequencing assays. Indeed, compared with conventional sequencing, the use of mass spectrometry 77 , allelespecific PCR 78 , or nextgeneration deep sequencing 79 markedly improves the specificity of predicting responses to these agents.
Targeting BRAF and/or MEK. Activating substitution mutations of valine 600 (V600) in BRAF are detected in approximately 50% of patients with advancedstage melanoma, and confer sensitivity to BRAF inhibitors, such as vemurafenib and dabra fenib (FIG. 2) 80 . Most BRAFmutant tumours are known to be responsive to the BRAF inhibitor vemura fenib; however, in an animal model, this inhibitor has been demonstrated to cause a paradoxical increase in MAPK activity and cell growth when an HRAS mutation is also present 81 . Furthermore, development of cutaneous squamouscell carcinomas and keratoacanthomas often occurs in patients treated with BRAF inhibitors 82 , and might result from stimulation of the growth of skin cells that possess RAS mutations. Concomitant treatment with a MEK inhibitor, such as trametinib, which is also approved by the FDA for the treatment of BRAF V600 mutated melanoma alone or in combination with dabrafenib, abrogates this growth stimulating effect in RASmutant cells and thus reduces the incidence of secondary skin cancers in patients with melanoma 83 . Moreover, findings of a phase III trial have demonstrated superior survival with use of dual BRAF-MEK blockade (median overall survival in the combina tion group was 25.1 months versus 18.7 months in the BRAFmonotherapy group), and reduced risk of cutan eous squamouscell carcinoma and keratoacanthoma (1% of patients in the combination therapy group versus 18% in the BRAFmonotherapy group) 84 . Unfortunately, approximately 30% of patients treated with dual BRAF-MEK inhibition experience disease progression within 6 months; in one study in 10 patients who developed rapidly progressive disease while receiv ing BRAF and MEK inhibitors, nine were found to have additional mutations in components of the MAPK path way, most commonly BRAF amplification or activating mutations in NRAS or MEK2 (REF. 85 ). These alterations were not found in the pretreatment tumour samples, but highsensitivity assays were not used 85 . Alternative RAF family inhibitors are in development, which might over come these resistance mechanisms 86 . Early detection of subclonal activating NRAS and MEK2 mutations could, therefore, enable stratification of the patients who would gain the greatest benefit from these inhibitors.
Detecting pre-existing drug resistance Despite numerous demonstrations of excellent anti neo plastic activity in some tumour types, targeted anti cancer drugs almost uniformly select for drugresistant subclones within a tumour, which eventually, and often rapidly, results in disease progression. For every molecu lar path way discussed, we have highlighted examples in which the frequency of preexisting drugresistance mutations can preferentially expand during exposure to the cognate drug and can thus predict treatment failure. Such mutations can be found in the tumour itself, and sometimes in plasma cellfree DNA derived from the tumour or in circulating tumour cells (CTCs) -as discussed in a later section of this manuscript. The limited technical ability to accurately quantify rare genetic variants has been a substantial bar rier to characterizing the extent to which preexisting drugresistant variants are present in different tumours, and precisely what clinical consequence the presence of these subclones foretells (FIG. 3) .
Detection of mutations in tumour biopsy tissue has typically been performed using Sanger sequencing; however, this methodology is optimal for detecting mutations that are present in most or all of the cells, with detection of mutations present in fewer than 25% of cells being unreliable 44 . Thus, assessments of hetero geneous tumours, or tumours intermixed with normal cells, can lead to falsenegative results. Newer methods of DNAsequence analysis, such as allelespecific PCR 87 , mass spectrometry 88 , Random Mutation Capture 89 , and digital droplet PCR 90 , afford greater sensitivity, but these techniques can only be used to survey a limited number of specified mutations. NGS offers the ability to deter mine the sequence of multiple genes simultaneously and can resolve mutations present in subpopulations of cells; however, this methodology is generally limited to detec tion of mutations present in >5% of cells, as errors during PCR amplification and sequencing generate background 'noise' , which obscures the detection of lowerfrequency variants (FIG. 3) 
44,91
. Molecular tagging methods have been developed that can lower the background error rate of NGS by approximately 20fold 92, 93 . These approaches are limi ted in their ability to resolve lowerlevel mutations, as they depend on amplification of singlestranded DNA in which the presence of DNA damage (such as oxida tive damage or abasic sites) can result in recurrent errors and miscalling (in correct identification) of variants. To overcome this limit ation, we have developed a techno logy termed 'Duplex Sequencing' that independently tags and sequences the two complementary strands of DNA 91 , as well as methods for efficient targeted capture and sequencing of individual exons of human genes 94 . This approach improves on the accuracy of NGS by >100,000fold, and enables detection of a single mutated base among >10 million sequenced nucleotides 91 . With Duplex Sequencing and other errorcorrection meth ods, additional DNAsequencer capa city is consumed relative to conventional NGS, as a single molecule of DNA is effectively sequenced multiple times to allow for error correction. By focusing on targeted regions of the genome that are likely to reflect actionable loci, how ever, the extra sequencing requirement is fairly modest. Highly sensitive assays will be essential to accurately characterize the pattern and timing of resistance to tar geted therapies, and will be a necessary aspect of future drug trials in order to optimize sequential ordering of thera pies, inform the choice of combination therapies, and to enable early adjustments in therapy at the first sign of drug resistance and disease progression.
Representative sampling of tumours
With liquid tumours (that is, leukaemias and some lym phomas), sampling a homogeneous population of the cancer is relatively simple, given the inherent mixing of cells in peripheral blood. The subclones within the bone marrow are not usually directly sampled, although the abundance of these subpopulations of cells seems to be similar to their frequency in the peripheral blood, at least in patients with acute myeloid leukaemia (AML) 95 . Obtaining a representative sample of a solid tumour is much more challenging, as the potential for spatial hetero geneity implies that any single biopsy could result in much of the diversity being missed. Furthermore, tumours evolve over time in response to treatment, but performing repeated biopsies to assess the associ ated molecular changes is generally impractical. Thus, treatment decisions are frequently made on the basis of mutations detected in biopsy samples taken at the ini tial time of diagnosis, despite the fact that many months might have passed. Analysis of tumour products pres ent in the circulation, an approach sometimes termed ' liquid biopsy' , is one way to circumvent these challenges relating to spatial h eterogeneity and tumour evolution.
The majority of advancedstage solid tumours release DNA into the systemic circulation, which is known as cir culating tumour DNA (ctDNA) 96 . With sufficiently large tumours, nearly all mutations identified as clonal events in tumour biopsies are accurately represented using this liquid biopsy approach 97, 98 . Subclonal mutations that confer resistance to targeted therapies have also been identified in ctDNA during treatment, and the abun dance of drugresistance mutations has been shown to change dynamically over the course of therapy 99 . Indeed, the major subclones comprising the tumour population are likely to be represented in ctDNA, although a direct comparison of subclonal structure in a tumour sample versus matched ctDNA remains to be reported.
The potential clinical utility of screening for subclonal drugresistance mutations in ctDNA is being increasingly demonstrated 100, 101 . For instance, KRAS mutations have frequently been found in ctDNA from patients with CRC -who were initially deemed KRAS wild type -at the time of clinical failure of EGFR blockade 102 ; in fact, multiple independent KRAS mutations were detected in ctDNA from some of the patients who developed resist ance to panitumumab 102 . In another study in patients with CRC 76 , mutations that confer resistance to cetuxi mab were identified in serum samples collected up to 10 months before radiographic disease progression. Similarly, preexisting MET amplification as a mech anism of resistance to EGFR blockade has also been observed in ctDNA before clinical treatment failure 103 . Intact CTCs can also be isolated, and analysis of these cells might be more informative than evaluation of cell free ctDNA in some situations. For example, in patients with NSCLC who are known to harbour EGFRactivating mutations, the mutation could be detected in CTCs from 92% of the patients, but the same mutation could be detected in cellfree ctDNA from only 32% 104 . In this study, genotyping of CTCs was also more sensitive than ctDNA for identifying the prototypical T790M resistance mutation in EGFR at, and before, disease progression 104 . In one interesting hybrid application in patients with breast cancer, capture of CTCs offered the opportunity to predict drug sensitivity by both empirical testing in cell culture experiments and through direct sequencing of CTC DNA for resistance mutations 105 . Finally, enrichment for certain cell subtypes before genotyping, such as CD34 + progenitor cells in samples from patients with CML, can also improve the predictive value of subclonal mutations 106 . Given the wellestablished spatial and temporal hetero geneity of solid tumours 14, 67, 68, 107, 108 , a reasonable question is whether individual biopsies, cellfree ctDNA, or CTCs can be truly representative of the full extent of genetic diversity within the tumour itself: biopsies are Coding-DNA sequence position 0 500 1,000 1,500 2,000 2,500 Nature Reviews | Clinical Oncology Figure 3 | The ability to detect mutations that are present at a low frequency depends on the assay error rate. a | Mutations present at a level substantially above technical background noise (error rate) of the assay (1% in this case) can be accurately quantified (i-ii), but those mutations with a prevalence below this threshold of detection (iii), or that are not present at all (iv), will be falsely assigned the background frequency. b | Genetic analysis via standard NGS has a background error rate of approximately 1%; at this error rate, with sufficiently deep sequencing, every genomic position would seem to be mutated near this level. In this example, exonic DNA encoding the active-site region of ABL1 was enriched using a double-capture protocol and sequenced by conventional NGS on an Illumina ® HiSeq ® 2500 sequencer 94 . c | Several biochemical error-correction strategies have recently been developed that reduce this background noise and enable a lower threshold of detection in order to capture extremely rare mutations. In this case, Duplex Sequencing of the same sample of tumour material across the same region of ABL1 reveals that only a single low-frequency mutation is actually present limited to a defined location within tumours and are taken at potentially restricted time points, and whether all subclonal cell populations within a tumour contribute equally to circulating cellfree DNA or are represented as CTCs remains unknown. Rigorously determining concordance of mutations among these sample sources would require deep sequencing of individual biopsy samples, cellfree DNA and CTCs, in conjunction with deep sequencing of the entire homogenized tumour. Fundamentally, encompassing the complete genetic diversity of a tumour will never be possible without sequencing DNA from every tumour cell individually; therefore, what level of sampling provides the most clini cally relevant approximation is an important practical question to be addressed in the coming years.
Issues in early detection of resistance History is rife with examples of wellintentioned diagnos tics that have ultimately borne out no benefit in terms of patient survival or quality of life. In some instances, tests have led to harm either directly, as a result of the diagnos tic assessment itself; indirectly, by leading to unnecessary interventions; or psychologically, by introducing worry among the patients about their future (without offering the ability to make changes to affect its course). Even seemingly intuitive tests supported by evidence from modern clinical trials, such as serum PSA screening for prostate cancer, have resulted in a complex mixture of conflicting guidelines based on different interpretations of the data. Healthcare costs within oncology are growing rapidly and any additional sources of expenditure need to be considered critically in the context of their overall value in improving clinical outcomes. In the following sections we consider some of these poignant issues.
Clinical actionability and utility
How often early detection of drugresistance muta tions will be clinically actionable and how frequently such action will meaningfully improve patient care are important questions. At present, our ability to identify lowlevel resistance mutations exceeds the capacity of the available therapeutic tools to prevent their outgrowth. A potential criticism of earlyresistance testing is that it would add cost, while only offering the ability to present a patient with the somber information that the treatment they are receiving is likely to fail after a short amount of time. Increasingly, however, alternate treatments do exist and could be instituted early if the development of drug resistance could be predicted and assessed over time. Repeated assessment of the various ABL1 kinase mutations that confer differential sensitivities to the five currently approved TKIs that target this protein repre sents an important example of this approach; currently, switching rationally between these drugs according to the particular resistance mutation that arises at a clonal level is commonplace in the clinic 38 . A further example in colon cancer involves the EGFR S492R mutation, which confers resist ance to the EGFR inhibitor cetuximab, but not to panitumumab 109 . With regard to the more common mode of resistance to antiEGFR antibodies mediated by KRAS mutations, patients with resistant CRCs seem to retain sensitivity to targeting of downstream signalling with MEK inhibitors, and early detection of emerging KRAS mutations has been proposed as an indication for initiation of treatment with antiMEK agents 76 . Pre existing MET amplification is another predictor of resist ance to antiEGFR agents in patients with CRC 103 , and would theor etically be actionable with the MET/VEGFR2 inhibitor cabozantinib, which is currently approved for the treatment of medullary thyroid cancer, or one of several MET inhibitors that are under investigation in clinical trials 110 .
As the number of new targeted antineoplastic agents continues to grow, so too will the number of options for countering emerging resistance induced by a prior treatment. For example, the remarkably successful intro duction within the past year of ibrutinib, which targets the Bruton tyrosine kinase (BTK) and is an effective treatment for patients with CLL and indolent lympho mas [111] [112] [113] , has already led to recognition of specific resist ance mech anisms. Mutation of the BTK target at cysteine 481 (C481S) or gainoffunction mutations in phospho lipase Cγ2 (PLCγ2; R665W and L845F), which is immedi ately downstream of BTK, results in ibrutinib resistance and disease progression 114, 115 . Inhibition of the down stream cyclindependent kinase 4 (CDK4)signalling pathway with palbociclib, an agent now approved by the FDA for the treatment of breast cancer, restores sensitivity to ibrutinib 115 . Likewise, second generation BTK inhibi tors are in development that maintain effectiveness in the presence of BTK C481 mutations 116 . In scenarios in which emerging drugresistance can be detected but no alternate therapy currently exists, sometimes other benefits to early recognition remain important. In patients with melanoma, tumours that have acquired resistance to BRAF V600E targeted therapy seem to become dependent on the BRAF inhibitor for growth, and withdrawal of the failing drug has, in fact, been shown to lead to tumour regression in melanoma xenograft models 117 ; thus, early detection of emer ging resistance could guide the decision on when to halt the use of a drug. More generally, nearly all drugs have adverse effects and an advanced warning of failure could, in some cases, improve a patient's overall quality of life by enabling earlier discontinuation of therapy to avoid exposing patients to unnecessary toxicities of an ultimately futile treatment. Similarly, earlier detection of resistance might improve prognostication of disease trajectory and such information could be used to help patients to better priori tize life goals. In addition, detec tion of preexisting resistance would enable clinical trials to be enriched for patients who lack detectable resistance, which would potentially decrease the number of patients that would be need to be enrolled in a trial and would, therefore, speed up the approval of novel therapeutics while decreasing costs.
Thresholds for treatment modification
The frequency of a drugresistance mutation that should necessitate a change of treatment when an alternate ther apy exists is another pertinent question. As discussed, we have only recently developed the capacity to readily detect subclonal drugresistance mutations, and thus much information about the effects of such mutations on clinical outcomes remains to be established. For example, how a clinician should respond to the scenario in which 0.1% of tumour cells in a population that is other wise sensitive to a targeted drug acquire a resistance mutation is unclear: a resistant clone is clearly emerging, but in this setting the majority of the tumour presumably con tinues to be suppressed by use of the current agent and the dilemma becomes how to balance future disease pro gression with prematurely abandoning one active drug among a finite pool of effective treatments.
Resistance mutations present in a small percentage of the cells in a tumour might be highly relevant if the mutation occurs in a cell that is capable of rapid growth. That tumours consist of multiple subpopulations of cells with differing growth rates is well established 95, 118 ; thus, a minority population of 'cancer stem cells' might give rise to most of the cells in a bulk tumour. The hypothesis that cancer stem cells are drivers of resistance is contro versial 119 , although this concept indicates a mechanism by which resistance in a minor subclone could quickly expand and cause clinical disease progression. On the other hand, some mutant subclones are likely to be more indolent. For example, some BCR-ABL1 kinase domain resistance mutations can be present at low levels before TKI treatment without leading to clinical relapse 120 . Likewise, in patients with AML, the AML-ETO fusion product, which is considered a driver of the disease, can remain detectable at low levels in the blood in patients who have been in complete remission for years 121 .
In the examples we have described in this Review, resistance mutations present at the lower limit of detection of the assays used, typically those present in 0.1-1% of cells, are clearly correlated with clinical out come. A solid tumour that is detectable on ima ging will typically consist of more than one billion cells, and 0.1% of the tumour thus comprises a population of at least 1 million cells. As highersensitivity techniques are morewidely adopted, the clinical relevance of a muta tional burden below one in 1,000 needs to be explored. Ultimately, determining when and how to act on muta tions that are present in a small fraction of cells is a con siderable challenge that will require prospective clinical trials to evaluate actionability. The clinical significance of rare subclonal mutations will likely depend on the spe cific disease, the magnitude of resistance conferred by a particular mutation and the effectiveness of subsequent secondline or thirdline agents. In some cases, addition of another agent to the current regimen -rather than a complete switch to a different therapy -could be preferable, although this approach might be limited by multiplicative toxicity of the drugs.
Is genetic testing for resistance futile?
In a large, genetically unstable tumour, every drug resistance mutation could potentially be preexisting; with this in mind, one might ask: what is the benefit of testing? Indeed, acquisition of an elevated mutation rate has been proposed as a common feature of carcino genesis 8, 122 , which implies that every possible mutation will be present in some subset of cells within a tumour. In this scenario, treatment with any targeted therapy might be expected to result in expansion of a drug resistant population and clinical progression. Some data support the concept of a 'mutator' phenotype in specific cancers [123] [124] [125] ; however, whether this is a general phenomenon remains to be demonstrated.
Of note, not every mutation that theoretically con fers drug resistance will be able to do so for a variety of reasons, including stochastic cell death, clonal interfer ence from other tumour cells, or because the mutation is not carried by a longlived tumour stem cell, which might entail only a small minority of a tumour popu lation. The fact that thousands of different resistance mutations do not simultaneously expand to a detectable level upon exposure to a targeted therapy supports this reasoning. Thus, a very large number of resistance muta tions might be present at an extremely low frequency, but those clones that have expanded to form a modestsized subpopulation comprising thousands to millions of cells among the billions of cells within a cancer are likely to be the most clinically relevant.
Independent of specific resistance mutations, quantify ing subclonal heterogeneity itself is of clinical importance. The frequency of clonal mutations has been examined comprehensively for most major cancer types 2, 3 , whereas the extent of subclonal hetero geneity within the DNAsequences of individual tumours has not. Greater subclonal diversity in a tumour might predict a higher likelihood of preexisting resistance to any conceivable targeted therapy. Such informa tion might be used to provide a rationale for accepting higher toxicity or increased costs of upfront targeted therapy combinations in certain settings. Presence of a high mutational load might also predict that a tumour is approaching an 'error catastrophe' threshold, such that further mutagenesis would be lethal to the tumour 30 , and thus might predict sensitivity to nontargeted cyto toxic chemotherapies. In the field of immunotherapy, patients with tumours bearing larger numbers of clonal mutations, and thus presumably more tumour specific neoantigens, respond especially well to immune checkpoint blockade 31, 32 . Whether a greater abundance of subclonal mutations similarly stimulates immune responses, or if, instead, such hetero geneity contrib utes to a pool of immuneevading resistance variants, merits examination.
Conclusions
Few other clinical disciplines have experienced such a foundationshifting effect of molecular medicine on daily practice as observed in oncology. In patients with some malignancies, such as certain lymphomas and breast cancers, the addition of molecularly targeted drugs to cytotoxic chemotherapy regimens has increased the rate of definitive cure; for others, such as those with CML, rationally designed therapies have turned a lifeending diagnosis into a largely chronic disease. For many patients with cancers, however, the benefit of such agents remains limited by the invariable evolution of resistance via outgrowth of subclonal mutants.
Developing methods of simultaneously suppress ing the many mechanisms that neoplastic cells have at their disposal for circumventing the available therapies will probably be the next frontier in cancer medicine. However, early identification of drugs that are failing or are likely to fail using the highsensitivity mutation detection tools that already exist should be a more immediate objective. In the short term, this approach will expedite the use of therapies that are more likely to succeed, prevent unnecessary toxicities, and limit the substantial costs of treatment -the latter of which is an unfortunate, and often underappreciated, adverse effect of targeted approaches in oncology.
Carrying out robust clinical trials of the large num ber of new targeted agents in development is an intim idating, and immediate, challenge. One possible means of improving trial efficiency would be to screen for and exclude patients with preexisting lowlevel drug resistance mutations, to enrich small study cohorts for those individuals who are most likely to benefit from the treatment. Another approach would be to capitalize on the currently unused interval between when a drug is introduced and when resistance becomes clinically apparent by using highsensitivity methods to detect early molecular changes in CTCs or cellfree ctDNA. Avoiding the need to wait for radiographic evidence of disease relapse would enable morerapid cycling of experimental therapies in humans, the most promis ing of which could then be validated in the context of t raditional survival end points.
Despite many limitations, personalized cancer ther apy remains the incontrovertible future of oncology, and is rapidly being implemented. Our current tools for addressing resistance remain imperfect, although it should be remembered that personalized medicine strives to deliver the best care to individual patients -not only in terms of identifying a drug we can use, but also regard ing the harms we can avoid. Moving forward, several shortterm actions could be implemented coordi nately to forestall the onset of drug resistance. These include: early detection of subclonal drugresistance mutations; routine implementation of highsensitivity liquid biopsies; moni toring patients for early disease recurrence; development of effective protocols for simultaneous treatment with multiple drugs; and, most importantly, continued efforts to expand our repertoire of targeted therapeutic options.
